Next 10 |
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team wil...
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter On track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the secon...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-04-16 18:25:52 ET Summary Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results ...
2024-04-12 09:01:35 ET More on premarket gainers & stock Cerus Corporation (CERS) Q4 2023 Earnings Call Transcript Globe Life Inc. (GL) Q4 2023 Earnings Call Transcript Alterity Therapeutics receives A$3.9M research & development tax incentive refund ...
2024-04-11 17:00:41 ET Gainers: Screaming Eagle Acquisition ( SCRM ) +9% . Lyell Immunopharma ( LYEL ) +8% . GlycoMimetics ( GLYC ) +5% . Sotera Health Company ( SHC ) +5% . Candel Therapeutics ( CADL ) +4% . Losers: ...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have ...
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024 Received Orphan Drug Designation for LYL845 for the treatment of melanoma Expect to submit IND for second generation ROR1-targeted CAR T-cell product in the first half of 2...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team wi...
News, Short Squeeze, Breakout and More Instantly...
Lyell Immunopharma Inc. Company Name:
LYEL Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical?stage T-cell reprogramming co...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team wil...
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarter On track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the secon...